Dr. John B. Haanen is consultant medical oncologist, CSO Immunotherapy and Research Group Leader in the Division of Molecular Oncology & Immunology at the Netherlands Cancer Institute (NKI) in Amsterdam. He is Professor of Translational Immunotherapy of Cancer at Leiden University Medical Centre, The Netherlands.
Dr. Haanen received his medical degree from the University of Leiden, then completed a PhD on human CD4+ helper T cells at the Department of Immunohematology & Blood Bank of the Leiden University Medical Centre and the DNAX Research Institute in California, USA.
He then trained in internal medicine at Leiden University Medical Centre and at Bronovo Hospital in The Hague, the Netherlands. He did a postdoctoral fellowship in tumour immunology at the Division of Immunology, followed by training in medical oncology at the Netherlands Cancer Institute, and was appointed as staff member at NKI in 2001. From 2009-2018 he was Head of the Division of Medical Oncology at NKI.
His research focuses on the translation of novel immunotherapy strategies into the clinical practice, especially adoptive cell transfer programs (TIL and TCR gene modified T cells, neoadjuvant immunotherapies and biomarker research. His clinical medical oncology practice is focused on melanoma and renal cell carcinoma patients.
Dr. Haanen is a Co-founder of the Amsterdam Biotherapeutics Unit and was Chairman of The Dutch Tumor Immunology Working Party for oncology for many years.
He serves on various national and international advisory boards and committees, was Scientific Chair of ESMO 2020 virtual Congress, is on the editorial board of Current Oncology Report, Kidney Cancer and ESMO Open, and is a member of the ESMO Gender Medicine Task Force.
He is Editor-in-Chief of ESMO IOTECH
Last update: February 2021